MAAAGI: Metformin for Abdominal Aortic Aneurysm Growth Inhibition
A multi-centre population-based open-label randomized controlled trial with allocation concealment and blinded outcome assessment will examine if up to 2g metformin daily slows AAA growth in patients with small AAAs who do not have diabetes.
|Condition or Disease||Intervention/Treatment||Phase|
Subjects with no history of diabetes will be recruited from a cohort of patients with diagnosed AAA and a maximum aortic diameter of 30-49mm for men and 30-44mm for women.
A total of 500 subjects with AAA will be included in the study, 250 in each study arm. Patients will be randomised to metformin or standard care in a 1:1 ratio.
CT imaging and AAA US will be performed at baseline, 24 months and end of study, as well as if necessary according to clinical routine. Study drug will start at baseline and continue through completion.
When all enrolled subjects have completed the 24-month follow-up (including imaging) an interim analysis will be performed to assess for efficacy and safety; if there is no trend towards a positive effect or signs of a harmful effect of metformin, the study will be stopped at this phase.
Arms and Interventions
|Experimental: Metformin target dose of 2g daily
Metformin tablets taken orally with target dose of 2g daily plus standard care
Metformin target dose 2 g daily
|Active Comparator: Standard care
Standard care includes help with smoking cessation if applicable; encouragement of physical activity and a healthy diet; blood pressure control; statin and anti-platelet therapy treatment if the patient have clinical manifestations of atherosclerotic disease.
Other: Standard care
Abdominal aortic aneurysm surveillance
Primary Outcome Measures
- Abdominal aortic aneurysm (AAA) diameter growth rate [5 years]
To examine if up to 2g metformin administered daily over a five-year period slows AAA growth measured as computed tomography (CT) imaging assessed AAA diameter (mm) in patients with small AAAs who do not have diabetes.
Secondary Outcome Measures
- Abdominal aortic aneurysm (AAA) volume growth rate [5 years]
To examine if up to 2g metformin administered daily over a five-year period slows AAA growth measured as computed tomography (CT) imaging assessed AAA volume (ml) in patients with small AAAs who do not have diabetes.
Provision of written informed consent.
Male and female patients.
Age 50-80 years.
Documented AAA Ø 30-49 mm for men and 30-44 mm for women.
Fasting p-glucose <7.0 mmol/L. Fasting is defined as no caloric intake for ≥8 h.
Short expected survival.
History of current or previous diabetes mellitus.
Current or previous use of metformin.
Not expected to tolerate metformin.
Contraindications to metformin treatment according to SmPC
Known or suspected connective tissue disorder (Marfans syndrome, etc), infected or inflammatory aneurysm, aneurysm development after aortic dissection or previous surgery of the infrarenal aorta.
Enrollment in either another investigational drug or medical device study or another investigational study of an approved drug or medical device within 30 days prior to enrollment of the current study.
If, in the opinion of the investigator, it is not in the patient's medical interest to participate in the study or the patient is unlikely to be able to comply with the study protocol.
Contacts and Locations
|1||Uppsala University Hospital||Uppsala||Sverige||Sweden|
Sponsors and Collaborators
- Uppsala University Hospital
- Principal Investigator: Jon Unosson, PhD, Uppsala University Hospital
Study Documents (Full-Text)